View ValuationColoplast 将来の成長Future 基準チェック /46Coloplast利益と収益がそれぞれ年間25.4%と6.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に36.1% 24.7%なると予測されています。主要情報25.4%収益成長率24.68%EPS成長率Medical Equipment 収益成長16.3%収益成長率6.4%将来の株主資本利益率36.08%アナリストカバレッジGood最終更新日23 Jun 2026今後の成長に関する最新情報お知らせ • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.お知らせ • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.お知らせ • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.お知らせ • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.お知らせ • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.お知らせ • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.すべての更新を表示Recent updatesお知らせ • Jun 04Coloplast Announces FDA Approval of Titan Prime Inflatable Penile ProsthesisColoplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available.お知らせ • May 13Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026.お知らせ • Mar 07Coloplast A/S Announces President ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.お知らせ • Mar 06Coloplast A/S Announces CEO ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.お知らせ • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.お知らせ • Dec 19Coloplast A/S Announces Executive ChangesColoplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space.お知らせ • Dec 05+ 2 more updatesColoplast A/S Approves Interim Dividend for the Year 2025Coloplast A/S approved at its AGM held on 4 December 2025 interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.お知らせ • Nov 04+ 1 more updateColoplast A/S Recommends Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 18.00 per share, which brings the total dividend for the year to DKK 23.00 per share, compared to DKK 22.00 per share last year.お知らせ • Oct 09Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made.お知らせ • Oct 01Coloplast A/S, Annual General Meeting, Dec 03, 2026Coloplast A/S, Annual General Meeting, Dec 03, 2026.お知らせ • Sep 30+ 3 more updatesColoplast A/S to Report Fiscal Year 2026 Results on Nov 05, 2026Coloplast A/S announced that they will report fiscal year 2026 results at 7:30 AM, Central European Standard Time on Nov 05, 2026お知らせ • May 06+ 1 more updateColoplast A/S Announces CEO ChangesColoplast A/S announced that CEO Kristian Villumsen has stepped down from his position as of May 5, 2025. The Board of Directors has appointed Lars Rasmussen as interim CEO. As the company enters a new strategy period, the Board has initiated the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as interim CEO. Accordingly, Lars Rasmussen steps down as Chair and will serve as an ordinary member of the Board. The new CEO of Coloplast is expected to be in place within the next 12 months, during which Lars Rasmussen will work closely with the executive leadership team to ensure continuity and accelerate momentum. He brings deep knowledge of Coloplast, having served as President & CEO from 2008 to 2018 and as part of executive management since 2001. During his tenure as interim CEO and ordinary Board member, Lars Rasmussen will step down as Chair of the Remuneration and Nomination Committee and as a member of the Audit Committee. Jette Nygaard-Andersen will assume these responsibilities during this period.お知らせ • Dec 05An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million. An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.お知らせ • Nov 15Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD PolicyColoplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed.お知らせ • Nov 06Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025お知らせ • Nov 05+ 2 more updatesColoplast A/S Recommends the Distribution of Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 17.00 per share, which brings the total dividend for the year to DKK 22.00 per share, compared to DKK 21.00 per share last year.お知らせ • Oct 15+ 2 more updatesColoplast A/S to Report First Half, 2025 Results on May 06, 2025Coloplast A/S announced that they will report first half, 2025 results on May 06, 2025お知らせ • Sep 27Coloplast A/S, Annual General Meeting, Dec 04, 2025Coloplast A/S, Annual General Meeting, Dec 04, 2025.お知らせ • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.お知らせ • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.お知らせ • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.お知らせ • Feb 01Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the USColoplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.お知らせ • Dec 08Coloplast A/S Approves the Distribution of Year-End DividendColoplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023.お知らせ • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.お知らせ • Sep 10+ 4 more updatesColoplast A/S to Report Q1, 2024 Results on Feb 09, 2024Coloplast A/S announced that they will report Q1, 2024 results at 7:30 AM, Central European Standard Time on Feb 09, 2024お知らせ • Sep 02Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLCColoplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees). Ulrik Falk, Morten Sløk and Niklas Mortensen of FIH Partners acted as financial advisors to Coloplast A/S. Jeppe Buskov, Morten Kofmann and Oliver Machholdt of Kromann Reumert acted as Lead Legal Advisor and PWC acted as financial advisor to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Logos Legal Services advised Kerecis on Icelandic law matters. Mark P. Holloway, Michael C. Labriola, Ross Davies, Sarah Lane, Stephen R. Heifetz, Michael S. Casey, Anne E. Seymour, Beau Buffier, Kimberley Biagioli, Andrew Poling, Martin Luff, Matt Staples and Paul S. Gadiock of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Kerecis. Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC on August 31, 2023.お知らせ • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.お知らせ • Jul 08Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).FIH Partners acted as transaction advisors, Kromann Reumert acted as Lead Legal Advisors, and PWC acted as financial advisors to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis.お知らせ • May 11Coloplast A/S Provides Earnings Guidance for the Fiscal 2023Coloplast A/S provided earnings guidance for the full fiscal year 2022/2023. For the period, the company reports organic revenue growth is now expected around 8% in constant exchange rates, from 7-8% previously. Reported growth in DKK is now expected to be 8-9%, from previously 9-10%, due to negative impact from currencies. Consequently, the reported EBIT margin is now expected in the 28-29% range, from previously 28-30%.お知らせ • Feb 04Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract InfectionsColoplast launches male catheter designed to reduce the risk of urinary tract infections. The new intermittent catheter Luja addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems. Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation. Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor. The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months. In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position. Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922).お知らせ • Feb 03Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23Coloplast A/S provided earnings guidance for the Fiscal Year 2022/23. For the period, Organic revenue growth is expected at 7% to 8% in constant exchange rates. Reported EBIT margin before special items is still expected at 28% to 30%, impacted by increasing input costs, especially raw materials and electricity in Hungary, partly offset by leverage, efficiency gains and prudent management of operating costs.お知らせ • Sep 09+ 4 more updatesColoplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023Coloplast A/S announced that they will report fiscal year 2023 results on Nov 09, 2023業績と収益の成長予測OTCPK:CLPB.F - アナリストの将来予測と過去の財務データ ( )DKK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202832,6736,4986,0407,509199/30/202730,6925,9615,5376,944209/30/202628,7423,1545,5886,412203/31/202628,0452,1065,9237,595N/A12/31/202527,8913,9895,3386,871N/A9/30/202527,8743,6365,2186,645N/A6/30/202527,8674,0754,9486,428N/A3/31/202527,7944,5444,8736,287N/A12/31/202427,4504,8841,6072,985N/A9/30/202427,0305,0521,4202,766N/A6/30/202426,3034,9671,3132,599N/A3/31/202425,5264,9651,0532,278N/A12/31/202325,0014,8684,2855,527N/A9/30/202324,5004,7832,9854,226N/A6/30/202324,3334,7843,2264,485N/A3/31/202324,0744,8013,6634,894N/A12/31/202223,5154,6263,2464,455N/A9/30/202222,5794,7063,9645,099N/A6/30/202221,6204,7813,8944,913N/A3/31/202220,6064,7463,7354,712N/A12/31/202119,8574,8964,2725,209N/A9/30/202119,4264,8253,3245,290N/A6/30/202118,9164,5613,1025,023N/A3/31/202118,5004,3043,1625,077N/A12/31/202018,5704,2413,0034,941N/A9/30/202018,5444,1973,8284,759N/A6/30/202018,5723,9493,8764,842N/A3/31/202018,7524,0203,8724,764N/A12/31/201918,3303,974N/A4,615N/A9/30/201917,9393,873N/A4,357N/A6/30/201917,5554,119N/A4,161N/A3/31/201917,1813,999N/A4,177N/A12/31/201816,8153,896N/A4,126N/A9/30/201816,4493,845N/A4,361N/A6/30/201816,1953,816N/A4,370N/A3/31/201815,8823,778N/A4,111N/A12/31/201715,7283,791N/A4,004N/A9/30/201715,5283,797N/A3,251N/A6/30/201715,2873,211N/A2,994N/A3/31/201715,0613,279N/A2,492N/A12/31/201614,7803,264N/A2,653N/A9/30/201614,6813,143N/A3,028N/A6/30/201614,5631,297N/A3,081N/A3/31/201614,4171,028N/A3,568N/A12/31/201514,264927N/A3,320N/A9/30/201513,909899N/A3,337N/A6/30/201513,5023,162N/A3,119N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CLPB.Fの予測収益成長率 (年間25.4% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: CLPB.Fの収益 ( 25.4% ) はUS市場 ( 18.9% ) よりも速いペースで成長すると予測されています。高成長収益: CLPB.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: CLPB.Fの収益 ( 6.4% ) US市場 ( 13% ) よりも低い成長が予測されています。高い収益成長: CLPB.Fの収益 ( 6.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CLPB.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 36.1 %)成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 08:57終値2026/06/18 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Coloplast A/S 20 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。40 アナリスト機関null nullABG Sundal CollierHassan Al-WakeelBarclaysAlexander KlebanBarclays37 その他のアナリストを表示
お知らせ • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.
お知らせ • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.
お知らせ • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
お知らせ • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.
お知らせ • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.
お知らせ • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.
お知らせ • Jun 04Coloplast Announces FDA Approval of Titan Prime Inflatable Penile ProsthesisColoplast announced FDA approval of Titan Prime, an inflatable penile prosthesis (IPP) that represents the company’s next-generation device and will be available in the U.S. in late 2026. Around 30 million men in the US experience ongoing difficulty in getting or keeping an erection firm enough for sexual activity. As an alternative to medication, some benefit from long-term treatment options such as an inflatable penile prosthesis, which is delivered through a single outpatient procedure. Inflatable Penile Prosthesis Titan Prime IPP is designed to emulate the appearance and performance of a natural erection, supporting device performance for patients, surgeons, and partners. Built with proprietary Bioflex – a polymer engineered for greater strength and durability than silicone – Titan Prime IPP delivers greater material strength than leading silicone competitors and withstands higher pressures to reinforce reliability. Titan Prime IPP preserves the rigidity and girth surgeons trust from Titan IPP today, while providing improved flaccid flexibility for comfort and concealability. The result is consistent, predictable outcomes across diverse male anatomies. Titan Prime is now FDA-approved and will be available through a phased launch to urologists and health care systems in the United States beginning in late 2026. Titan Prime IPP is approved for use in the United States by the FDA. Coloplast is pursuing regulatory approvals in other countries, where the product is not yet available.
お知らせ • May 13Coloplast A/S Announces Interim Dividend for the First Half Ended March 31, 2026Coloplast A/S announced that it will pay a interim dividend of DKK 5.00 per share, for a total dividend pay-out of DKK 1,127 million for the first half ended March 31, 2026.
お知らせ • Mar 07Coloplast A/S Announces President ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.
お知らせ • Mar 06Coloplast A/S Announces CEO ChangesColoplast A/S's board of directors announced the appointment of Gavin Wood as the new President and Chief Executive Officer (CEO) of the Coloplast Group, effective May 1, 2026. Gavin Wood will take over from interim CEO Lars Rasmussen, who has been in the role since May 5, 2025. Gavin Wood has spent two decades in different leadership roles in Johnson & Johnson, most recently as Company Group Chairman of Johnson & Johnson MedTech EMEA, a multi-billion-dollar business with more than 7,000 employees working across three business units: Surgery, Orthopedics, and Cardiovascular & Specialty Solutions. Earlier in his career, he led the Ethicon Wound Closure & Healing team as Worldwide President, and prior to that, he served as Executive Vice President, Commercial, at Mölnlycke. Gavin Wood currently serves as Vice Chair of the MedTech Europe trade association. He holds a Bachelor of Arts degree in Law from Carleton University, Canada and an MBA from Queen’s University, Canada. He is Canadian by birth, currently lives in Switzerland, and he will be relocating to Denmark. Lars Rasmussen will continue to lead Coloplast as interim CEO until the end of April.
お知らせ • Feb 06Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2025-2026Coloplast A/S provided earnings guidance for the fiscal year 2025-2026. For the year, the company expects around 7% EBIT growth in constant currencies.
お知らせ • Dec 19Coloplast A/S Announces Executive ChangesColoplast A/S announced changes to its Executive Leadership Team, affecting the Interventional Urology business and the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group, including Global Operations, Atos, and People & Culture, and in her role in the Executive Leadership Team. An external search is currently on-going to identify a new leader of the global People & Culture function. Dorthe Rønnau will have her last day at Coloplast at the end of February 2026, where Mads Mikkelsen, Vice President, People & Culture, Chronic Care Commercial, will take over the interim leadership of the global People & Culture organisation until a permanent successor has been identified. After more than a decade in Coloplast and more than three decades in the global life science industry, Tommy Johns, Executive Vice President of Interventional Urology, will retire early next year. Tommy Johns has been instrumental in identifying his successor, ensuring a period of overlap between Tommy and his successor to ensure a thorough handover prior to Tommy’s final day with Coloplast early next year. Kevin Hardage will step into the role of Executive Vice President of Interventional Urology. He joins Coloplast on February 9, 2026. Kevin brings extensive experience from the global MedTech industry, including senior leadership experience from Teleflex in the urology space.
お知らせ • Dec 05+ 2 more updatesColoplast A/S Approves Interim Dividend for the Year 2025Coloplast A/S approved at its AGM held on 4 December 2025 interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.
お知らせ • Nov 04+ 1 more updateColoplast A/S Recommends Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 18.00 per share, which brings the total dividend for the year to DKK 23.00 per share, compared to DKK 22.00 per share last year.
お知らせ • Oct 09Coloplast A/S Announces Interim CEO Lars Rasmussen Will Step Down from the Board At the Upcoming Annual General Meeting on December 4, 2025Coloplast interim CEO Lars Rasmussen has informed the Coloplast Board of Directors that he will not stand for re-election as board member at the upcoming annual general meeting on December 4, 2025. Lars Rasmussen will, as announced earlier this year, continue in the role as interim CEO until a new CEO of Coloplast is in place. Jette Nygaard-Andersen will continue in the role of interim Chair and, together with the Board of Directors, lead Coloplast in the coming period, as the company enters into its next strategic period of long-term, sustainable growth and value creation. Jette Nygaard-Andersen has been a member of the Board since December 2015 and interim Chair since May 5, 2025. The Board of Directors are unanimously supportive of the announced changes. The search for Coloplast’s new CEO is progressing according to plan, and an announcement will follow once a decision has been made.
お知らせ • Oct 01Coloplast A/S, Annual General Meeting, Dec 03, 2026Coloplast A/S, Annual General Meeting, Dec 03, 2026.
お知らせ • Sep 30+ 3 more updatesColoplast A/S to Report Fiscal Year 2026 Results on Nov 05, 2026Coloplast A/S announced that they will report fiscal year 2026 results at 7:30 AM, Central European Standard Time on Nov 05, 2026
お知らせ • May 06+ 1 more updateColoplast A/S Announces CEO ChangesColoplast A/S announced that CEO Kristian Villumsen has stepped down from his position as of May 5, 2025. The Board of Directors has appointed Lars Rasmussen as interim CEO. As the company enters a new strategy period, the Board has initiated the search for a new CEO to lead Coloplast into its next phase of long-term, sustainable growth and value creation. To ensure continuity, the Chair of the Board Lars Rasmussen assumes the role as interim CEO. Accordingly, Lars Rasmussen steps down as Chair and will serve as an ordinary member of the Board. The new CEO of Coloplast is expected to be in place within the next 12 months, during which Lars Rasmussen will work closely with the executive leadership team to ensure continuity and accelerate momentum. He brings deep knowledge of Coloplast, having served as President & CEO from 2008 to 2018 and as part of executive management since 2001. During his tenure as interim CEO and ordinary Board member, Lars Rasmussen will step down as Chair of the Remuneration and Nomination Committee and as a member of the Audit Committee. Jette Nygaard-Andersen will assume these responsibilities during this period.
お知らせ • Dec 05An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B).An undisclosed buyer acquired Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024. For the period ending September 30, 2024, Coloplast's Skin Care business reported total revenue of DKK 400 million. An undisclosed buyer completed the acquisition of Coloplast's Skin Care business from Coloplast A/S (CPSE:COLO B) on December 3, 2024.
お知らせ • Nov 15Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD PolicyColoplast A/S announced on 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD) policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population. The final LCD policy confirms the introduction of a technical qualification and a clinical efficacy qualification, proposed in a draft LCD policy2 earlier this year. The final decision also introduces two separate lists for covered products for DFUs and covered products for VLUs. In addition, the application limit has been expanded from 4 to 8 and the duration of treatment has been increased from 12 to 16 weeks in the final policy. The implementation date of the final policy is set to 12 February 2025. Based on the final evaluation, Kerecis is included on the final list of covered products for DFUs, however, Kerecis has not been included on the covered list for VLUs. Sales related to VLUs in the out-patient setting currently represent a low-single digit portion of the total Kerecis’ sales. Kerecis has an ongoing clinical study on VLUs and will attempt to get coverage for VLUs as soon as the study is completed.
お知らせ • Nov 06Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025Coloplast A/S announced that they will report nine months, 2025 results on Aug 19, 2025
お知らせ • Nov 05+ 2 more updatesColoplast A/S Recommends the Distribution of Year-End DividendThe Board of Directors of Coloplast A/S recommended a year-end dividend of DKK 17.00 per share, which brings the total dividend for the year to DKK 22.00 per share, compared to DKK 21.00 per share last year.
お知らせ • Oct 15+ 2 more updatesColoplast A/S to Report First Half, 2025 Results on May 06, 2025Coloplast A/S announced that they will report first half, 2025 results on May 06, 2025
お知らせ • Sep 27Coloplast A/S, Annual General Meeting, Dec 04, 2025Coloplast A/S, Annual General Meeting, Dec 04, 2025.
お知らせ • Aug 20Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S re-affirmed earnings guidance for the fiscal year 2023/24. For the period, the company expects organic revenue growth to be around 8%. Reported growth in DKK is expected to be 10% to 11%.
お知らせ • May 08+ 2 more updatesColoplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
お知らせ • Feb 09+ 1 more updateColoplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24Coloplast A/S reaffirmed earnings guidance for the fiscal year 2023/24. For the year, the organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions.
お知らせ • Feb 01Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the USColoplast A/S aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. Changing demographics and an aging population are leading to a higher demand for healthcare services, putting significant strain on healthcare systems. In the US, chronic wounds are reported to affect 10.5 million patients annually1, while 2.5 million patients develop a pressure injury in acute care facilities each year2. Therefore, it is critical for healthcare providers to choose products that simplify their workflows and deliver the best possible care for their patients.
お知らせ • Dec 08Coloplast A/S Approves the Distribution of Year-End DividendColoplast A/S approved the distribution of year-end dividend of DKK 16 per share of nominally DKK 1, at the AGM held on December 7, 2023.
お知らせ • Nov 11+ 1 more updateColoplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024Coloplast A/S provided earnings guidance for Fiscal year 2023-2024. For the year company expects, organic revenue growth of around 8% and an EBIT margin of 27%-28%.
お知らせ • Sep 10+ 4 more updatesColoplast A/S to Report Q1, 2024 Results on Feb 09, 2024Coloplast A/S announced that they will report Q1, 2024 results at 7:30 AM, Central European Standard Time on Feb 09, 2024
お知らせ • Sep 02Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLCColoplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees). Ulrik Falk, Morten Sløk and Niklas Mortensen of FIH Partners acted as financial advisors to Coloplast A/S. Jeppe Buskov, Morten Kofmann and Oliver Machholdt of Kromann Reumert acted as Lead Legal Advisor and PWC acted as financial advisor to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis. Logos Legal Services advised Kerecis on Icelandic law matters. Mark P. Holloway, Michael C. Labriola, Ross Davies, Sarah Lane, Stephen R. Heifetz, Michael S. Casey, Anne E. Seymour, Beau Buffier, Kimberley Biagioli, Andrew Poling, Martin Luff, Matt Staples and Paul S. Gadiock of Wilson Sonsini Goodrich & Rosati, P.C. acted as legal advisor to Kerecis. Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC on August 31, 2023.
お知らせ • Aug 17Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023Coloplast A/S provided earnings guidance for the fiscal year 2022/2023. Organic revenue growth continues to be expected around 8%. Reported revenue growth is still expected at 8% to 9%.
お知らせ • Jul 08Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion on July 7, 2023. The total enterprise value for 100% ownership of Kerecis amounts to up to $1.3 billion, consisting of $1.2 billion upfront cash payment and an earnout potential of maximum $100 million dependent on financial performance in FY 2023/24. The transaction is expected to be financed through an equity capital raise of around DKK 9 billion ($1.3 billion). Following the expected acquisition, Kerecis will operate as a stand-alone business unit under its own identity and brand. Kerecis reported a revenue of DKK 510 million ($74.36 million) in FY 2021/22. Closing of the transaction is subject to customary regulatory approvals and an acceptance threshold of at least 90%, and is anticipated in Q4 2022/23. Kerecis’ Board of Directors has recommended to the company’s minority shareholders to sell their shares in Kerecis to Coloplast. 77% of Kerecis’ shareholders have committed to sell their shares to Coloplast. The acquisition is expected to be margin dilutive short-term for Coloplast. The transaction is expected to be increasingly EPS accretive from FY 2026/27. Coloplast’s financial guidance for FY 2022/23 excluding transaction related costs is unchanged. Special items for FY 2022/23 are expected to increase by DKK 50 million due to transaction related costs (advisory fees).FIH Partners acted as transaction advisors, Kromann Reumert acted as Lead Legal Advisors, and PWC acted as financial advisors to Coloplast. Danske Bank will act as Sole Global Coordinator in connection with the equity capital raise and Joint Bookrunner together with Nordea. J.P. Morgan acted as exclusive financial advisor to Kerecis.
お知らせ • May 11Coloplast A/S Provides Earnings Guidance for the Fiscal 2023Coloplast A/S provided earnings guidance for the full fiscal year 2022/2023. For the period, the company reports organic revenue growth is now expected around 8% in constant exchange rates, from 7-8% previously. Reported growth in DKK is now expected to be 8-9%, from previously 9-10%, due to negative impact from currencies. Consequently, the reported EBIT margin is now expected in the 28-29% range, from previously 28-30%.
お知らせ • Feb 04Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract InfectionsColoplast launches male catheter designed to reduce the risk of urinary tract infections. The new intermittent catheter Luja addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems. Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation. Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor. The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months. In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position. Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922).
お知らせ • Feb 03Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23Coloplast A/S provided earnings guidance for the Fiscal Year 2022/23. For the period, Organic revenue growth is expected at 7% to 8% in constant exchange rates. Reported EBIT margin before special items is still expected at 28% to 30%, impacted by increasing input costs, especially raw materials and electricity in Hungary, partly offset by leverage, efficiency gains and prudent management of operating costs.
お知らせ • Sep 09+ 4 more updatesColoplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023Coloplast A/S announced that they will report fiscal year 2023 results on Nov 09, 2023